301 related articles for article (PubMed ID: 35688559)
1. Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells.
He M; Soni B; Schwalie PC; Hüsser T; Waltzinger C; De Silva D; Prinz Y; Krümpelmann L; Calabro S; Matos I; Trumpfheller C; Bacac M; Umaña P; Levesque MP; Dummer R; van den Broek M; Gasser S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688559
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
Tada H; Aiba S; Shibata K; Ohteki T; Takada H
Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
[TBL] [Abstract][Full Text] [Related]
3. Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.
Hänel G; Angerer C; Petry K; Lichtenegger FS; Subklewe M
Cancer Immunol Immunother; 2022 Jul; 71(7):1705-1718. PubMed ID: 34821951
[TBL] [Abstract][Full Text] [Related]
4. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
5. The influence of CD40 ligation and interferon-gamma on functional properties of human monocyte-derived dendritic cells activated with polyinosinic-polycytidylic acid.
Dragicević A; Dzopalić T; Vasilijić S; Vucević D; Bozić B; Majstorović I; Balint B; Colić M
Vojnosanit Pregl; 2011 Apr; 68(4):301-8. PubMed ID: 21627015
[TBL] [Abstract][Full Text] [Related]
6. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
7. Combined TLR-3/TLR-8 Signaling in the Presence of α-Type-1 Cytokines Represents a Novel and Potent Dendritic Cell Type-1, Anti-Cancer Maturation Protocol.
Fevžer T; Poženel P; Zajc K; Tešić N; Švajger U
Cells; 2022 Feb; 11(5):. PubMed ID: 35269457
[TBL] [Abstract][Full Text] [Related]
8. Human CD34
van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
[TBL] [Abstract][Full Text] [Related]
9. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.
Anguille S; Smits EL; Cools N; Goossens H; Berneman ZN; Van Tendeloo VF
J Transl Med; 2009 Dec; 7():109. PubMed ID: 20021667
[TBL] [Abstract][Full Text] [Related]
10. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.
Napolitani G; Rinaldi A; Bertoni F; Sallusto F; Lanzavecchia A
Nat Immunol; 2005 Aug; 6(8):769-76. PubMed ID: 15995707
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
[TBL] [Abstract][Full Text] [Related]
12. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
Boullart AC; Aarntzen EH; Verdijk P; Jacobs JF; Schuurhuis DH; Benitez-Ribas D; Schreibelt G; van de Rakt MW; Scharenborg NM; de Boer A; Kramer M; Figdor CG; Punt CJ; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2008 Nov; 57(11):1589-97. PubMed ID: 18322684
[TBL] [Abstract][Full Text] [Related]
13. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
15. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.
Yoshio S; Kanto T; Kuroda S; Matsubara T; Higashitani K; Kakita N; Ishida H; Hiramatsu N; Nagano H; Sugiyama M; Murata K; Fukuhara T; Matsuura Y; Hayashi N; Mizokami M; Takehara T
Hepatology; 2013 May; 57(5):1705-15. PubMed ID: 23213063
[TBL] [Abstract][Full Text] [Related]
16. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.
Xu S; Koldovsky U; Xu M; Wang D; Fitzpatrick E; Son G; Koski G; Czerniecki BJ
Surgery; 2006 Aug; 140(2):170-8. PubMed ID: 16904966
[TBL] [Abstract][Full Text] [Related]
17. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.
Re F; Strominger JL
J Immunol; 2004 Dec; 173(12):7548-55. PubMed ID: 15585882
[TBL] [Abstract][Full Text] [Related]
18. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
19. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC.
Lauterbach H; Bathke B; Gilles S; Traidl-Hoffmann C; Luber CA; Fejer G; Freudenberg MA; Davey GM; Vremec D; Kallies A; Wu L; Shortman K; Chaplin P; Suter M; O'Keeffe M; Hochrein H
J Exp Med; 2010 Nov; 207(12):2703-17. PubMed ID: 20975040
[TBL] [Abstract][Full Text] [Related]
20. TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.
Surendran N; Simmons A; Pichichero ME
Innate Immun; 2018 May; 24(4):240-251. PubMed ID: 29673285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
